e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go
Martin Kolditz, Tobias Welte
Source:
Eur Respir J, 57 (2) 2003778; 10.1183/13993003.03778-2020
Journal Issue:
February
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Martin Kolditz, Tobias Welte. Preventing cardiovascular events after pneumonia with aspirin: one step forward, but still many to go. Eur Respir J, 57 (2) 2003778; 10.1183/13993003.03778-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Community acquired pneumonia: an increased risk for subsequent cardiovascular events?
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database
Source: Eur Respir J, 57 (2) 2002795; 10.1183/13993003.02795-2020
Year: 2021
QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Platelet count as an evolution marker of late mortality and cardiovascular events after an episode of community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Incidence, risk factors and outcomes of cardiovascular events in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Year: 2009
Novel drug-induced respiratory emergencies
Source: Annual Congress 2006 - Drug-induced lung injury – new aspects
Year: 2006
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Acute Pneumonia and PSI: is it posible to prevent a cardiovascular event?
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Comunity acquired legionella pneumonia: cardiovascular events and survival
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
Rates of major cardiovascular events in severe asthma: US real-world and clinical trial populations
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
COPD and respiratory viral infections as risk factors for the development of cardiovascular events
Source: Virtual Congress 2020 – Prognosis and integrated management of COPD
Year: 2020
Management of acute pulmonary thrombo-embolic disease (PTE) linking mortality risk to treatment strategies
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
Long term course of (chronic) thromboembolic pulmonary hypertension, preceded by silent or unrecognized thromboembolic events
Source: Annual Congress 2009 - Pulmonary embolism
Year: 2009
Frequency of cardiovascular events in hospitalised patients with community acquired pneumonia
Source: Annual Congress 2009 - Complications of respiratory infections: impact of comorbidities and infections caused by Aspergillus
Year: 2009
Macrolide therapy for pneumonia: balancing benefits with cardiovascular risks
Source: International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights
Year: 2014
Influence of chronic cardiovascular diseases (CVD) on course and outcome of community-acquired pneumonia (CAP)
Source: International Congress 2017 – The acute patient: the clinical point-of-view
Year: 2017
Is community-acquired pneumonia an independent risk factor for cardiovascular disease?
Source: Eur Respir J 2012; 39: 187-196
Year: 2012
Is community-acquired pneumonia an independent risk factor for cardiovascular disease?
Source: Eur Respir J 2011; 39: 187-196
Year: 2012
Interleukin-6 levels as an evolution marker of late mortality and cardiovascular events after an episode of community-acquired pneumonia.
Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Year: 2018
Late Breaking Abstract - Incidence, risk factors and thrombotic load of pulmonary embolism in patients hospitalized with COVID-19
Source: Virtual Congress 2021 – Insights into pulmonary embolism
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept